Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc. reported a net loss of $16.6 million for fiscal year 2024, an improvement from a $20.0 million loss in the prior year. Revenue was minimal at $170K, down from $1.0 million in FY 2023, primarily from license agreements. Operating expenses totaled $18.4 million, with research and development costs of $7.9 million and general and administrative expenses of $10.4 million. The company ended the year with $16.0 million in cash and cash equivalents and total assets of $17.7 million. A significant forward-looking event is the proposed acquisition by Kuva Labs Inc., announced on March 6, 2026, for $5.00 per share plus a contingent value right, which, if completed, would result in delisting from Nasdaq. The company's financial statements include a going concern qualification, noting substantial doubt about its ability to continue operations beyond twelve months without additional funding.

Key Takeaways